Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in Chinese adults with anti-AQP4 positive NMOSD
NCT06724809Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of eculizumab in neuromyelitis optica spectrum disorder (NMOSD), sponsored by Alexion Pharmaceuticals. Started Jan 2025; status: active, not recruiting.
02
Drugs
eculizumab
03
Conditions
neuromyelitis optica spectrum disorder (NMOSD)
Beyond the preview
Go deeper on NCT06724809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06724809.